Data are presented indicating that the growth of 5 out of 5 murine lymphoid tumors can be inhibited in a synergistic fashion in vitro by combined treatment with the iron chelator deferoxamine (DFO) and an immunoglobulin G (IgG) monoclonal anti-transferrin receptor antibody (ATRA). A two-way doselresponse analysis shows that the ATRA becomes more efficient as an inhibitor with increasing doses of DFO. Flow cytometric studies further support the view that IgG ATRAS impair transferrin receptor (TR) function by causing TR down-modulation and degradation, even when the presence of DFO acts to promote increased cell surface TR expression. It is also shown that an IgG ATRA is nearly as effective as an IgM ATRA in inhibiting tumor cell growth when used in combination with DFO. Finally, studies with the iron chelator picolinic acid show H E UPTAKE of iron from an exogenous source is T crucial to the growth of normal and neoplastic cells.'
Iron is of importance in DNA synthesis because it modulates ribonucleotide reductase activity.* Iron is also crucial for normal mitochondrial electron transport and oxidative pho~phorylation.~ Recent data from several sources suggest that iron deprivation may be a useful strategy in the treatment of neoplasms, particularly those of hematopoietic rigi in.^.^ In one report the iron chelator deferoxamine (DFO) was used with some encouraging results in the treatment of a case of acute l e~k e m i a .~
In another set of studies, a monoclonal immunoglobulin M (IgM) anti-transferrin receptor antibody (ATRA) was shown to have some efficacy in the treatment of a murine lymphoma in vivo. 5 Most recently, a combination of the iron chelator parabactin and the multivalent IgA ATRA 4216 was shown to have supra-additive growth inhibitory effects against the HL60 cell line in vitro. 6 The combined use of an ATRA and iron chelator might be an attractive therapeutic strategy because it could potentially allow for the utilization of lower doses of the chelator, the reagent with the most apparent toxicity.' We, like Taetle et a1,6 have been studying the effects of combination treatment with ATRAS and an iron chelator on the growth of several hematopoietic tumors in vitro, and we present several new findings that have arisen from our work.
MATERIALS AND METHODS
Lymphoid tumors. The B-cell tumors 702, NFS-I, and 695 were obtained from Drs Bryan Van Ness (University of Minnesota, Minneapolis), Herbert Morse (National Institutes of Health, Bethesda, MD), and Richard Lynch (University of Iowa, Iowa City), respectively. The T-cell tumors Ba18 and EL4 were also obtained from Dr Lynch. Each has been maintained in our laboratory for several years.
The bacterial iron siderophore deferoxamine (produced under the name Desferal by Ciba-Geigy Inc, Summit, NJ) was obtained from the Pharmacy of the University of Iowa Hospitals and Clinics. A fresh vial containing 500 mg of lyophilized DFO was used for each experiment and was resuspended with distilled water to a 100 mg/mL stock solution before dilution in tissue culture media. The iron chelator picolinic acid (2-pyridine
Iron chelators.
that it produces only additive, or very slightly supraadditive, effects when used in combination with the ATRA. Therefore, these studies not only continue to suggest that combination chelator1 ATRA therapy warrants further investigation as a tool in the therapy of hematopoietic malignancies, but also make the following new points: ( Cells harvested from culture were stained with C2F2 and a fluorescein-conjugated F(ab'), preparation of mouse anti-rat IgG (Jackson Immunoresearch, West Grove, PA). In those cases where C2F2 was included in the culture, we (and others) have shown that most of the transferrin receptors are already bound by the ATRA, and this can be detected by the addition of the 
RESULTS
The combination of an IgC ATRA and DFO causes synergistic inhibition of growth of five lymphoid tumors.
The initial experiments were undertaken as a result of prior studies we had performed indicating that IgG ATRAs could be potent inhibitors of normal lymphocyte a c t i~a t i o n .~,~ Each tumor to be tested was evaluated beforehand with respect to its sensitivity to deferoxamine.
The data in Fig 1 show that the inhibition of thymidine incorporation produced by submaximal concentrations of DFO is dramatically enhanced in the presence of the IgG ATRA for each of the five tumors tested. The ATRA alone, even at the relatively high concentration of 25 pg/mL, produces only modest inhibition, ranging from 0 to 26%,
Concentration of Deferoxamine (Wml)
Concentration of Deferoxamine (pg/ml) Although at certain doses of DFO the effect of the reagents combined produces very impressive synergistic inhibition, a more conservative way to gauge the interaction of the two reagents is to compare the estimated dose of DFO required to produce half-maximal inhibition in the presence of the ATRA versus that required in the absence of the ATRA, and to establish an index of enhancement by dividing the latter number by the former ( Table 1 ). Note that although the dose of DFO required to produce half-maximal inhibition of a given tumor varies to some extent between experiments, the rank order of tumor sensitivity to DFO alone is maintained, as is the rank order of the indices of enhancement. It appears that all of the tumors tested show a reproducible synergistic enhancement of inhibition when the two agents are used in combination, and that certain tumors reproducibly show more enhancement than others. Other experiments also show that OKT9, an IgG anti-human ATRA, shows indices of enhancement of 2.0 and 3.0 in two experiments with the HL60 leukemia; and YEI, another IgG anti-mouse ATRA, shows an index of enhancement of 2.0 in experiments with the 702 and NFS tumors.
ATRA inhibitory eficiency rises with increasing doses of DFO. We next wanted to determine the dose range of the ATRA required to produce synergistic inhibition in these experiments. The data presented in Fig 2 show that, as the dose of DFO is increased (from 5 pg/mL up to 25 pg/mL) the amount of ATRA required to produce half-maximal inhibition progressively decreases to an apparent minimum of about 100 to 200 ng/mL. The latter observation appears to indicate that as the dose of DFO increases, so does the inhibitory efficiency of the ATRA. 
Tumor growth inhibition is correlated with IgG ATRAinduced transferrin receptor (TR) down-modulation.
We next wanted to learn more about the mechanisms involved in IgG ATRA/DFO synergism. Therefore, we undertook flow cytometric studies of changes in surface expression of the T R resulting from the treatments under study. The data represented in Fig 3A show that the IgG ATRA alone causes about a threefold decrease in surface receptor expression when compared with the control. This result was expected from prior
The data represented in Fig 3B show that DFO alone causes a threefold increase in surface receptor expression (compare curve 1 in panel B with curve 1 in panel A). This result was also expected from previous work.I3 Curve 2 in panel B shows the effect of the reagent combination. It is clear that ATRA-induced receptor downmodulation persists and dominates despite the presence of a stimulus for enhanced receptor expression.
Growth inhibition produced by IgG ATRAIDFO combination is nearly equivalent to that seen with an IgM ATRA and DFO. It has been observed that bivalent IgG ATRAs, as single agents, are poor inhibitors of tumor cell growth and the data presented here continue to support that view."." Therefore, having made the unexpected observation that an IgG ATRA can cause synergistic growth inhibition when used with an iron chelator, we next asked how such inhibition compared with that produced by an IgM ATRA in combination with DFO. Multivalent IgM or IgA ATRAs, or IgG ATRAs further cross-linked by anti-Ig reagents, have been thought to be better growth inhibitors.lO," For our study we chose an IgM ATRA that has recently been shown to have anti-tumor effects in vivo.5 The data presented in Fig 4 show that the IgM ATRA is only modestly more effective than the IgG ATRA in that 99% inhibition of thymidine incorporation occurs at a slightly lower concentration of DFO. represents data obtained from cells in the presence of normal rat IgG while curve 2 represents cells exposed to the IgG ATRA (both reagents at 25 pg/mL). (B) Curve 1 represents cells exposed to DFO alone ( 5 pg/mL) while curve 2 represents cells exposed to DFO and the ATRA (5 and 25 pg/mL, respectively). In the same experiment, lower doses of DFO alone produced smaller increases in surface expression of the TR, while higher doses produced only slightly higher increases; the combination of DFO/ATRA produced receptor down-modulation at all doses of DFO (not shown). Very similar data were obtained in two repetitions of the same protocol with the NFS tumor, and related studies have shown that the other four tumors also show receptor down-modulation when treated with DFO and the IgG ATRA. the IgM ATRA R17-208. Both ATRAs were used at a concentration of 25 pg/mL. C2F2 produced 17% inhibition, and R17-208 produced 18% inhibition, in the absence of DFO. This degree of suppression is a plateau maximum for this antibody with this tumor; no further increase in inhibition occurs at 50 or 100 pg/mL even though normal T lymphocytes are far more sensitive to this same antibody prep? Very similar data were obtained in a repetition of the same protocol.
Iron chelators vary in their capacity to produce synergistic growth inhibition. Because the iron chelators DFO and parabactin cause synergistic or supra-additive growth inhibition, respectively, when used in combination with an ATRA (the current data and reference 6), we next wished to ascertain whether another iron chelator, picolinic acid (PLA), would also produce synergy. PLA is an iron chelator that has been shown to have anti-tumor activity in vivo.I4
The data shown in Fig 5 represent a dose-response study with PLA performed in the presence or absence of the IgG ATRA in a manner similar to the prior studies with DFO. The results, although somewhat surprising, are clear; the effects of PLA and the IgG ATRA are either additive or, at most, very slightly supra-additive. Therefore, PLA does not produce the same degree of synergistic inhibition seen with DFO.
DISCUSSION
The studies presented here confirm and considerably extend the work recently reported by Taetle et al; they reported supra-additive inhibition of HL60 growth in vitro when that tumor was exposed to a combination of the iron chelator parabactin and the multivalent IgA ATRA 42/6.6 We now show that synergistic inhibition of tumor growth also occurs, in all cases tested, when five murine lymphoid tumors are exposed to DFO and the IgG ATRA C2F2 in vitro. The observation that an IgG ATRA can produce profound inhibition of tumor growth when used in combination with an iron chelator is both novel and completely unexpected. It was unexpected because while we and others have shown that IgG ATRAs can act as potent inhibitors of normal lymphocyte activation, such reagents have nonetheless consistently failed to produce impressive inhibition of tumor cell growth when used alone.*'"
The present findings clearly provide further support for the generally accepted view that IgG ATRAs impair cell function by causing down-modulation and degradation of the TR, thereby impairing the delivery of iron."-'* The observation that receptor down-modulation can be associated with significant growth inhibition stands in sharp contrast to the current idea that only "hyper cross-linking" and build-up of receptors at the cell surface, without internalization, will lead to significant growth inhibition.6.'0i'' Such hyper crosslinking is thought to be achievable only with multivalent IgA or IgM ATRAs and, as a result, there has been essentially no consideration of therapeutic usage of IgG ATRAs. This is important because IgG ATRAs have a better capacity to diffuse into extra-vascular tissue spaces and may therefore, for example, be better at affecting tumor cells in lymphatics.
The fact that DFO produces synergy is significant. Despite its occasionally severe toxicity,' DFO is the only chelator that is relatively well-understood from a clinical point of view, and it is therefore more likely that a move to clinical trials of combination iron deprivation therapy will occur if DFO is initially used in the combination. It is likely that other chelators, which are of diverse chemical origins, would have to undergo extensive toxicity testing as single agents before being used in combination therapy. The studies with PLA clearly suggest that not all iron chelators will produce synergy with ATRAs. This raises the question as to whether some additional characteristic of chelators such as DFO, beyond that of depleting intracellular iron stores, plays a crucial role in determining the existence of synergy with an ATRA. Therefore, it is clear that each chelator/ATRA combination will have to be compared for its effects on iron uptake and that such studies should be an integral part of a detailed analysis of chelator effects on T R messenger R N A induction, levels of cell surface expression of TRs, and rate of receptor down-modulation in the presence of the ATRA. It is conceivable, for example, that one chelator has a more pronounced effect on receptor turnover velocity and/or alters the intracellular receptor traffic pattern. We currently have experiments planned to investigate each of these questions.
It remains to be seen whether combined ATRA/chelator therapy will be clinically practical. The synergistic inhibition of tumor growth that has been observed in vitro might also lead to synergistic toxicity in vivo. However, it is also possible that toxicity may be decreased with the combination, especially if lower doses of the iron chelator can be used. Thus, it would appear that further study of combined ATRA/ chelator therapy is warranted.
